Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer

PURPOSE: Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have demonstrated potent activity against TKI resistance mediated by EGFR T790M. We studied whether noninvasive genotyping of cell-free plasma DNA (cfDNA) is a useful biomarker for prediction of outco...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Oncol
Auteurs principaux: Oxnard, Geoffrey R., Thress, Kenneth S., Alden, Ryan S., Lawrance, Rachael, Paweletz, Cloud P., Cantarini, Mireille, Yang, James Chih-Hsin, Barrett, J. Carl, Jänne, Pasi A.
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2016
Sujets:
ORIGINAL REPORTS
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5035123/
https://ncbi.nlm.nih.gov/pubmed/27354477
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.66.7162
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires